1951-25-3 (2-Butylbenzofuran-3yl) (4-(2-(diethylamino) ethoxy)-3,5 diiodophenyl) methanone 98%

We would like to introduce our company Srini Pharmaceuticals Pvt. Ltd., was established in 1995 and USFDA approved (6 times successful inspections), TGA , EU GMP and WHO GMP approved and fully integrated API manufacturing pharmaceutical company, located just about 55 KM’s away from the Pharma hub of India, Hyderabad. The litsed API’s are manufactured in our own USFDA,TGA, EUGMP approved manufacturing facility located at Srini Pharmaceuticals Pvt Ltd, Survey No: 247, Choutuppal - 508252,Telangana, India. It is my pleasure to inform you that we have been audited by USFDA very successfully with Zero 483 observations from 14th to 18th October, 2019 ( Last Inspection). Please find below the details of USFDA approvals from 2005 onwards as below. USFDA approvals 1. May, 2005 : 1st approval 2. April, 2009 : 2nd approval 3. July, 2012 : 3rd approval 4. April, 2015 : 4th approval 5. October, 2017 : 5th approval 6. October 2019 : 6th approval TGA approvals 1. November, 2008 1st Approval 2. May 2012 2nd approval and valid till date (Continuously getting Desk top approvals and valid up to May 2024) We are glad to inform you that our facility got inspected by EU GMP and received the EU GMP certification. We have EUGMP certification for Apixaban, Rivaroxaban, Ranolazine, Dabigatran, Dextromethorphan HBr, Esomeprazole Magnesium Trihydrate, Levetiracetam and Omeprazole We have CEPS for Esomeprazole magnesium trihydrate, Dextromethorphan hydrobromide , Pregabalin, Omeprazole ,Labetalol ,Rivaroxaban. I have Attached our E- Brochure which consists of our range of APIs as well as Intermediates for your kind review and reference, We can assure you that we can become a good source for your Regulatory, ROW & Domestic markets and we can support with all the required